Vasoconstrictor cannabinoid analogs

Details Vasoconstrictor cannabinoid analogs Vasoconstrictor cannabinoid analogs

2006-09-19

2006-09-19

Keys, Rosalynd (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ether doai

C514S719000, C514S720000, C514S721000, C568S644000, C568S645000, C568S646000

Reexamination Certificate

active

07109245

ABSTRACT:
Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising:wherein dashed lines independently represent either a single or a double bond, R1is a lower alkyl, R2is a lower alkyl, R3is a lower alkyl or halogen, R4is a lower alkyl or hydrogen, R5is a lower alkyl or hydrogen, R6is a hydrogen, lower alkyl or halogen, and R7is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.

REFERENCES:
patent: 2304669 (1942-12-01), Adams
patent: 3919322 (1975-11-01), Brossi et al.
patent: 4025516 (1977-05-01), Razdan et al.
patent: 4978332 (1990-12-01), Luck et al.
patent: 5227537 (1993-07-01), Stoss et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5342971 (1994-08-01), Herlt et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5939429 (1999-08-01), Kunos et al.
patent: 6274635 (2001-08-01), Travis
patent: 6563009 (2003-05-01), Kunos et al.
patent: WO 99/53917 (1999-10-01), None
patent: WO 01/03690 (2001-01-01), None
Bukoski et al., “CD1Receptor Antagonist SR141716A Inhibits Ca2+-Induced Relaxation in CB1Receptor-Deficient Mice,”Hypertension 39:251-257 (2002).
Childers et al., “A Novel Approach to the Synthesis of the Cannabinoids,”J. Org. Chem. 49:5276-5277 (1984).
Consroe et al., “Antiepileptic Potential of Cannabidiol Analogs,”J. Clin. Pharmacol. 21:428S-436S (1981).
Ferraro et al., “The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vivo and In Vitro Study,”Cereb. Cortex 11:728-733 (2001).
Járai et al., “Cannabinoid-Induced Mesenteric Vasodilation Through an Endothelial Site Distinct from CB1 OR CB2 Receptors,”PNAS 96:14136-14141 (1999).
Korte et al., “Chemical Classification of Plants, XXIX. Hashish, 8, Synthesis of DL-Cannabidiol and its Methyl Homologs,”Justus Liebigs Annalen der Chemie 693:165-170 (1966).
Martin et al., “Structure-Anticonvulsant Activity Relationships of Cannabidiol Analogs,”NIDA Research Monograph 79:48-58 (1987).
Srebnik et al., “Base-Catalysed Double-Bond Isomerizations of Cannabinoids: Structural and Stereochemical Aspects,”J. Chem. Soc. Perkin Trans.—:2881-2886 (1984).
Varga et al., “Platelet- and Macrophage-Derived Endogenous Cannabinoids are Involved in Endotoxin-Induced Hypotension,”FASEB J. 12:1035-1044 (1998).
Chemical Abstracts, 65:7221e.
Burstein et al., “Prostaglandins and Cannabis XV. Comparison of Enantiomeric Cannabinoids in Stimulating Prostaglandin Synthesis in Fibroblasts,” Life Sciences, 39(19):1813-1823 (1986).
Mechoulam et al., “Enantiomeric Cannabinoids: Stereospecificity of Psychotropic Activity,” Experientia, 44:762-764 (1988).
Thakur et al., “Enantiomeric Resolution of a Novel Chiral Cannabinoid Receptor Ligand,” J. Biochem. Biophys. Methods, 54:415-422 (2002).

Affiliated with

Also associated with

Rating

Vasoconstrictor cannabinoid analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vasoconstrictor cannabinoid analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vasoconstrictor cannabinoid analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3534062